Androgen receptor: Structure, role in prostate cancer and drug discovery

Acta Pharmacologica Sinica

Volumn 36, Issue 1, 2015, Pages 3-23

  Tan, Mh Eileen ^a,b   Li, Jun ^a   Xu, H Eric ^b,c   Melcher, Karsten ^b   Yong, Eu Leong ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b VAN ANDEL RESEARCH INSTITUTE   (United States)

^c SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

androgen; androgen receptor; antiandrogen; castration resistance; drug discovery; nuclear receptor; prostate cancer; rational drug design; structural biology

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR AGONIST; ANTIANDROGEN; BICALUTAMIDE; ENZALUTAMIDE; FLUDROCORTISONE; HORMONE RECEPTOR AFFECTING AGENT; UNCLASSIFIED DRUG;

ADVANCED CANCER; AMINO TERMINAL SEQUENCE; ANDROGEN INSENSITIVITY SYNDROME; ANDROGEN SYNTHESIS; CANCER GROWTH; CANCER RESISTANCE; CANCER STAGING; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; COMPUTER MODEL; DIMERIZATION; DNA BINDING; DRUG APPROVAL; DRUG DESIGN; DRUG DEVELOPMENT; DRUG STRUCTURE; FRAMESHIFT MUTATION; GROWTH; HIGH THROUGHPUT SCREENING; HORMONE DETERMINATION; HORMONE STRUCTURE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INDEL MUTATION; KARYOTYPE 46,XY; LIGAND BINDING; NONHUMAN; PROSTATE CANCER; PROSTATE CARCINOMA; PROTEIN DOMAIN; PROTEIN EXPRESSION; REVIEW; RNA SPLICING; SOMATIC MUTATION; X RAY CRYSTALLOGRAPHY; ANIMAL; CHEMISTRY; MALE; METABOLISM; PROCEDURES; PROSTATE TUMOR;

ANDROGENS; ANIMALS; DRUG DISCOVERY; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 84920394601     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2014.18     Document Type: Review

References (206)

1. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, et al. The nuclear receptor superfamily: the second decade. Cell 1995; 83: 835-9.
2. Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994; 63: 451-86.
3. Nuclear Receptors Nomenclature Committee. A unified nomenclature system for the nuclear receptor superfamily. Cell 1999; 97: 161-3.
4. Rosner W, Hryb DJ, Khan MS, Nakhla AM, Romas NA. Sex hormonebinding globulin: anatomy and physiology of a new regulatory system. J Steroid Biochem Mol Biol 1991; 40: 813-20.
5. Baker ME. Albumin, steroid hormones and the origin of vertebrates. J Endocrinol 2002; 175: 121-7.
6. Srinivas-Shankar U, Wu FC. Drug insight: testosterone preparations. Nat Clin Pract Urol 2006; 3: 653-65.
7. Shang Y, Myers M, Brown M. Formation of the androgen receptor transcription complex. Mol Cell 2002; 9: 601-10.
8. Dehm SM, Tindall DJ. Molecular regulation of androgen action in prostate cancer. J Cell Biochem 2006; 99: 333-44.
9. Wang Q, Carroll JS, Brown M. Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell 2005; 19: 631-42.
10. van Royen ME, van Cappellen WA, de Vos C, Houtsmuller AB, Trapman J. Stepwise androgen receptor dimerization. J Cell Sci 2012; 125: 1970-9.
11. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004; 25: 276-308.
12. Beato M, Herrlich P, Schutz G. Steroid hormone receptors: many actors in search of a plot. Cell 1995; 83: 851-7.
13. Brinkmann AO. Molecular basis of androgen insensitivity. Mol Cell Endocrinol 2001; 179: 105-9.
14. McPhaul MJ, Marcelli M, Tilley WD, Griffin JE, Wilson JD. Androgen resistance caused by mutations in the androgen receptor gene. FASEB J 1991; 5: 2910-5.
15. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
16. Lubahn DB, Joseph DR, Sullivan PM, Willard HF, French FS, Wilson EM. Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science 1988; 240: 327-30.
17. Brown CJ, Goss SJ, Lubahn DB, Joseph DR, Wilson EM, French FS, et al. Androgen receptor locus on the human X chromosome: regional localization to Xq11-12 and description of a DNA polymorphism. Am J Hum Genet 1989; 44: 264-9.
18. Migeon BR, Brown TR, Axelman J, Migeon CJ. Studies of the locus for androgen receptor: localization on the human X chromosome and evidence for homology with the Tfm locus in the mouse. Proc Natl Acad Sci USA 1981; 78: 6339-43.
19. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002; 20: 3001-15.
20. McEwan IJ. Molecular mechanisms of androgen receptor-mediated gene regulation: structure-function analysis of the AF-1 domain. Endocr Relat Cancer 2004; 11: 281-93.
21. He B, Kemppainen JA, Voegel JJ, Gronemeyer H, Wilson EM. Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH2-terminal domain. J Biol Chem 1999; 274: 37219-25.
22. Sasaki M, Kaneuchi M, Sakuragi N, Fujimoto S, Carroll PR, Dahiya R. The polyglycine and polyglutamine repeats in the androgen receptor gene in Japanese and Caucasian populations. Biochem Biophys Res Commun 2003; 312: 1244-7.
23. Hsing AW, Gao YT, Wu G, Wang X, Deng J, Chen YL, et al. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res 2000; 60: 5111-6.
24. Chang CS, Kokontis J, Liao ST. Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors. Proc Natl Acad Sci USA 1988; 85: 7211-5.
25. Davies P, Watt K, Kelly SM, Clark C, Price NC, McEwan IJ. Consequences of poly-glutamine repeat length for the conformation and folding of the androgen receptor amino-terminal domain. J Mol Endocrinol 2008; 41: 301-14.
26. Werner R, Holterhus PM, Binder G, Schwarz HP, Morlot M, Struve D, et al. The A645D mutation in the hinge region of the human androgen receptor (AR) gene modulates AR activity, depending on the context of the polymorphic glutamine and glycine repeats. J Clin Endocrinol Metab 2006; 91: 3515-20.
27. Choong CS, Kemppainen JA, Zhou ZX, Wilson EM. Reduced androgen receptor gene expression with first exon CAG repeat expansion. Mol Endocrinol 1996; 10: 1527-35.
28. Callewaert L, Christiaens V, Haelens A, Verrijdt G, Verhoeven G, Claessens F. Implications of a polyglutamine tract in the function of the human androgen receptor. Biochem Biophys Res Commun 2003; 306: 46-52.
29. Lavery DN, McEwan IJ. Structural characterization of the native NH2-terminal transactivation domain of the human androgen receptor: a collapsed disordered conformation underlies structural plasticity and protein-induced folding. Biochemistry 2008; 47: 3360-9.
30. Reid J, Kelly SM, Watt K, Price NC, McEwan IJ. Conformational analysis of the androgen receptor amino-terminal domain involved in transactivation. Influence of structure-stabilizing solutes and proteinprotein interactions. J Biol Chem 2002; 277: 20079-86.
31. Lavery DN, McEwan IJ. The human androgen receptor AF1 transactivation domain: interactions with transcription factor IIF and molten-globule-like structural characteristics. Biochem Soc Trans 2006; 34: 1054-7.
32. Lavery DN, McEwan IJ. Structure and function of steroid receptor AF1 transactivation domains: induction of active conformations. Biochem J 2005; 391: 449-64.
33. Chandra V, Huang P, Hamuro Y, Raghuram S, Wang Y, Burris TP, et al. Structure of the intact PPAR-gamma-RXR-nuclear receptor complex on DNA. Nature 2008; 456: 350-6.
34. Chandra V, Huang P, Potluri N, Wu D, Kim Y, Rastinejad F. Multidomain integration in the structure of the HNF-4alpha nuclear receptor complex. Nature 2013; 495: 394-8.
35. Uversky VN. Multitude of binding modes attainable by intrinsically disordered proteins: a portrait gallery of disorder-based complexes. Chem Soc Rev 2011; 40: 1623-34.
36. Bevan CL, Hoare S, Claessens F, Heery DM, Parker MG. The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol Cell Biol 1999; 19: 8383-92.
37. McEwan IJ, Gustafsson J. Interaction of the human androgen receptor transactivation function with the general transcription factor TFIIF. Proc Natl Acad Sci USA 1997; 94: 8485-90.
38. Simental JA, Sar M, Lane MV, French FS, Wilson EM. Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem 1991; 266: 510-8.
39. Callewaert L, Van Tilborgh N, Claessens F. Interplay between two hormone-independent activation domains in the androgen receptor. Cancer Res 2006; 66: 543-53.
40. Doesburg P, Kuil CW, Berrevoets CA, Steketee K, Faber PW, Mulder E, et al. Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor. Biochemistry 1997; 36: 1052-64.
41. He B, Kemppainen JA, Wilson EM. FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J Biol Chem 2000; 275: 22986-94.
42. Wilson EM. Analysis of interdomain interactions of the androgen receptor. Methods Mol Biol 2011; 776: 113-29.
43. Zhou ZX, Lane MV, Kemppainen JA, French FS, Wilson EM. Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. Mol Endocrinol 1995; 9: 208-18.
44. Langley E, Kemppainen JA, Wilson EM. Intermolecular NH2-/carboxylterminal interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity. J Biol Chem 1998; 273: 92-101.
45. Shaffer PL, Jivan A, Dollins DE, Claessens F, Gewirth DT. Structural basis of androgen receptor binding to selective androgen response elements. Proc Natl Acad Sci USA 2004; 101: 4758-63.
46. Claessens F, Alen P, Devos A, Peeters B, Verhoeven G, Rombauts W. The androgen-specific probasin response element 2 interacts differentially with androgen and glucocorticoid receptors. J Biol Chem 1996; 271: 19013-6.
47. Verrijdt G, Schoenmakers E, Haelens A, Peeters B, Verhoeven G, Rombauts W, et al. Change of specificity mutations in androgenselective enhancers. Evidence for a role of differential DNA binding by the androgen receptor. J Biol Chem 2000; 275: 12298-305.
48. Schoenmakers E, Verrijdt G, Peeters B, Verhoeven G, Rombauts W, Claessens F. Differences in DNA binding characteristics of the androgen and glucocorticoid receptors can determine hormonespecific responses. J Biol Chem 2000; 275: 12290-7.
49. Claessens F, Denayer S, Van Tilborgh N, Kerkhofs S, Helsen C, Haelens A. Diverse roles of androgen receptor (AR) domains in ARmediated signaling. Nucl Recept Signal 2008; 6: e008.
50. Jenster G, Trapman J, Brinkmann AO. Nuclear import of the human androgen receptor. Biochem J 1993; 293: 761-8.
51. Zhou ZX, Sar M, Simental JA, Lane MV, Wilson EM. A liganddependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH2-terminal and carboxyl-terminal sequences. J Biol Chem 1994; 269: 13115-23.
52. Marte B. Passage through the nuclear pore. Nat Cell Biol 2001; 3: E135.
53. Ni L, Llewellyn R, Kesler CT, Kelley JB, Spencer A, Snow CJ, et al. Androgen induces a switch in the androgen receptor from cytoplasmic retention to nuclear import. Mol Cell Biol 2013; 33: 4766-78.
54. Cutress ML, Whitaker HC, Mills IG, Stewart M, Neal DE. Structural basis for the nuclear import of the human androgen receptor. J Cell Sci 2008; 121: 957-68.
55. Haelens A, Tanner T, Denayer S, Callewaert L, Claessens F. The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor. Cancer Res 2007; 67: 4514-23.
56. Clinckemalie L, Vanderschueren D, Boonen S, Claessens F. The hinge region in androgen receptor control. Mol Cell Endocrinol 2012; 358: 1-8.
57. Matias PM, Donner P, Coelho R, Thomaz M, Peixoto C, Macedo S, et al. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem 2000; 275: 26164-71.
58. Fang H, Tong W, Branham WS, Moland CL, Dial SL, Hong H, et al. Study of 202 natural, synthetic, and environmental chemicals for binding to the androgen receptor. Chem Res Toxicol 2003; 16: 1338-58.
59. Sathya G, Chang CY, Kazmin D, Cook CE, McDonnell DP. Pharmacological uncoupling of androgen receptor-mediated prostate cancer cell proliferation and prostate-specific antigen secretion. Cancer Res 2003; 63: 8029-36.
60. Singh SM, Gauthier S, Labrie F. Androgen receptor antagonists (antiandrogens): structure-activity relationships. Curr Med Chem 2000; 7: 211-47.
61. Gao W, Bohl CE, Dalton JT. Chemistry and structural biology of androgen receptor. Chem Rev 2005; 105: 3352-70.
62. Cantin L, Faucher F, Couture JF, de Jesus-Tran KP, Legrand P, Ciobanu LC, et al. Structural characterization of the human androgen receptor ligand-binding domain complexed with EM5744, a rationally designed steroidal ligand bearing a bulky chain directed toward helix 12. J Biol Chem 2007; 282: 30910-9.
63. VC M. The history of clinical endocrinology: a comprehensive account of endocrinology from earliest times to the present day. Carnforth: Parthenon Press; 1993.
64. Baulieu EE, Lasnizki I, Robel P. Metabolism of testosterone and action of metabolites on prostate glands grown in organ culture. Nature 1968; 219: 1155-6.
65. Bruchovsky N, Wilson JD. The conversion of testosterone to 5-alphaandrostan-17-beta-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem 1968; 243: 2012-21.
66. Grino PB, Griffin JE, Wilson JD. Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology 1990; 126: 1165-72.
67. Sack JS, Kish KF, Wang C, Attar RM, Kiefer SE, An Y, et al. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci USA 2001; 98: 4904-9.
68. Pereira de Jesus-Tran K, Cote PL, Cantin L, Blanchet J, Labrie F, Breton R. Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity. Protein Sci 2006; 15: 987-99.
69. Schwabe JW. Transcriptional control: how nuclear receptors get turned on. Curr Biol 1996; 6: 372-4.
70. Li Y, Lambert MH, Xu HE. Activation of nuclear receptors: a perspective from structural genomics. Structure 2003; 11: 741-6.
71. Bourguet W, Germain P, Gronemeyer H. Nuclear receptor ligandbinding domains: three-dimensional structures, molecular interactions and pharmacological implications. Trends Pharmacol Sci 2000; 21: 381-8.
72. Wang Z, Benoit G, Liu J, Prasad S, Aarnisalo P, Liu X, et al. Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors. Nature 2003; 423: 555-60.
73. Cano LQ, Lavery DN, Bevan CL. Mini-review: Foldosome regulation of androgen receptor action in prostate cancer. Mol Cell Endocrinol 2013; 369: 52-62.
74. Renaud JP, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H, et al. Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature 1995; 378: 681-9.
75. Wagner RL, Apriletti JW, McGrath ME, West BL, Baxter JD, Fletterick RJ. A structural role for hormone in the thyroid hormone receptor. Nature 1995; 378: 690-7.
76. Nascimento AS, Dias SM, Nunes FM, Aparicio R, Ambrosio AL, Bleicher L, et al. Structural rearrangements in the thyroid hormone receptor hinge domain and their putative role in the receptor function. J Mol Biol 2006; 360: 586-98.
77. Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, Collins JL, et al. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 2001; 98: 13919-24.
78. Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 1997; 387: 733-6.
79. Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 1996; 87: 953-9.
80. Estebanez-Perpina E, Moore JM, Mar E, Delgado-Rodrigues E, Nguyen P, Baxter JD, et al. The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor. J Biol Chem 2005; 280: 8060-8.
81. Zhou XE, Suino-Powell KM, Li J, He Y, Mackeigan JP, Melcher K, et al. Identification of SRC3/AIB1 as a preferred coactivator for hormoneactivated androgen receptor. J Biol Chem 2010; 285: 9161-71.
82. Hur E, Pfaff SJ, Payne ES, Gron H, Buehrer BM, Fletterick RJ. Recognition and accommodation at the androgen receptor coactivator binding interface. PLoS Biology 2004; 2: E274.
83. He B, Minges JT, Lee LW, Wilson EM. The FXXLF motif mediates androgen receptor-specific interactions with coregulators. J Biol Chem 2002; 277: 10226-35.
84. He B, Gampe RT Jr, Kole AJ, Hnat AT, Stanley TB, An G, et al. Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol Cell 2004; 16: 425-38.
85. Slagsvold T, Kraus I, Bentzen T, Palvimo J, Saatcioglu F. Mutational analysis of the androgen receptor AF-2 (activation function 2) core domain reveals functional and mechanistic differences of conserved residues compared with other nuclear receptors. Mol Endocrinol 2000; 14: 1603-17.
86. Estebanez-Perpina E, Arnold LA, Nguyen P, Rodrigues ED, Mar E, Bateman R, et al. A surface on the androgen receptor that allosterically regulates coactivator binding. Proc Natl Acad Sci USA 2007; 104: 16074-9.
87. Grosdidier S, Carbo LR, Buzon V, Brooke G, Nguyen P, Baxter JD, et al. Allosteric conversation in the androgen receptor ligand-binding domain surfaces. Mol Endocrinol 2012; 26: 1078-90.
88. Buzon V, Carbo LR, Estruch SB, Fletterick RJ, Estebanez-Perpina E. A conserved surface on the ligand binding domain of nuclear receptors for allosteric control. Mol Cell Endocrinol 2012; 348: 394-402.
89. Tyagi RK, Lavrovsky Y, Ahn SC, Song CS, Chatterjee B, Roy AK. Dynamics of intracellular movement and nucleocytoplasmic recycling of the ligand-activated androgen receptor in living cells. Mol Endocrinol 2000; 14: 1162-74.
90. Saporita AJ, Zhang Q, Navai N, Dincer Z, Hahn J, Cai X, et al. Identification and characterization of a ligand-regulated nuclear export signal in androgen receptor. J Biol Chem 2003; 278: 41998-2005.
91. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998; 95: 927-37.
92. Kauppi B, Jakob C, Farnegardh M, Yang J, Ahola H, Alarcon M, et al. The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J Biol Chem 2003; 278: 22748-54.
93. Xu HE, Stanley TB, Montana VG, Lambert MH, Shearer BG, Cobb JE, et al. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature 2002; 415: 813-7.
94. Hodgson MC, Shen HC, Hollenberg AN, Balk SP. Structural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor. Mol Cancer Ther 2008; 7: 3187-94.
95. Osguthorpe DJ, Hagler AT. Mechanism of androgen receptor antagonism by bicalutamide in the treatment of prostate cancer. Biochemistry 2011; 50: 4105-13.
96. Kuil CW, Mulder E. Mechanism of antiandrogen action: conformational changes of the receptor. Mol Cell Endocrinol 1994; 102: R1-5.
97. Zhu P, Baek SH, Bourk EM, Ohgi KA, Garcia-Bassets I, Sanjo H, et al. Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 2006; 124: 615-29.
98. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33-9.
99. Dotzlaw H, Moehren U, Mink S, Cato AC, Iniguez Lluhi JA, Baniahmad A. The amino terminus of the human AR is target for corepressor action and antihormone agonism. Mol Endocrinol 2002; 16: 661-73.
100. Quigley CA, De Bellis A, Marschke KB, el-Awady MK, Wilson EM, French FS. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev 1995; 16: 271-321.
101. Hughes IA, Davies JD, Bunch TI, Pasterski V, Mastroyannopoulou K, MacDougall J. Androgen insensitivity syndrome. Lancet 2012; 380: 1419-28.
102. Hiort O. Clinical and molecular aspects of androgen insensitivity. Endocr Dev 2013; 24: 33-40.
103. McPhaul MJ. Androgen receptor mutations and androgen insensitivity. Mol Cell Endocrinol 2002; 198: 61-7.
104. Gottlieb B, Beitel LK, Nadarajah A, Paliouras M, Trifiro M. The androgen receptor gene mutations database: 2012 update. Hum Mutat 2012; 33: 887-94.
105. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991; 352: 77-9.
106. Zajac JD, Fui MN. Kennedy's disease: clinical significance of tandem repeats in the androgen receptor. Adv Exp Med Biol 2012; 769: 153-68.
107. Finsterer J. Bulbar and spinal muscular atrophy (Kennedy's disease): a review. Eur J Neurol 2009; 16: 556-61.
108. Lobaccaro JM, Lumbroso S, Belon C, Galtier-Dereure F, Bringer J, Lesimple T, et al. Androgen receptor gene mutation in male breast cancer. Hum Mol Genet 1993; 2: 1799-802.
109. Goulioumis AK, Varakis J, Goumas P, Papadaki H. Androgen receptor in laryngeal carcinoma: could there be an androgen-refractory tumor? ISRN Oncol 2011; 2011: 180518.
110. Chen PJ, Yeh SH, Liu WH, Lin CC, Huang HC, Chen CL, et al. Androgen pathway stimulates microRNA-216a transcription to suppress the tumor suppressor in lung cancer-1 gene in early hepatocarcinogenesis. Hepatology 2012; 56: 632-43.
111. Garolla A, Ferlin A, Vinanzi C, Roverato A, Sotti G, Artibani W, et al. Molecular analysis of the androgen receptor gene in testicular cancer. Endocr Relat Cancer 2005; 12: 645-55.
112. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62: 220-41.
113. Hoffman RM. Clinical practice. Screening for prostate cancer. N Engl J Med 2011; 365: 2013-9.
114. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011; 103: 117-28.
115. Silva Neto B, Koff WJ, Biolchi V, Brenner C, Biolo KD, Spritzer PM, et al. Polymorphic CAG and GGC repeat lengths in the androgen receptor gene and prostate cancer risk: analysis of a Brazilian population. Cancer Invest 2008; 26: 74-80.
116. Schleutker J. Polymorphisms in androgen signaling pathway predisposing to prostate cancer. Mol Cell Endocrinol 2012; 360: 25-37.
117. Price DK, Chau CH, Till C, Goodman PJ, Baum CE, Ockers SB, et al. Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial. J Urol 2010; 184: 2297-302.
118. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996; 28: 251-65.
119. Huggins C. Endocrine-induced regression of cancers. Cancer Res 1967; 27: 1925-30.
120. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002; 168: 9-12.
121. Zeliadt SB, Buist DS, Reid RJ, Grossman DC, Ma J, Etzioni R. Biopsy follow-up of prostate-specific antigen tests. Am J Prev Med 2012; 42: 37-43.
122. Rubin MA, Maher CA, Chinnaiyan AM. Common gene rearrangements in prostate cancer. J Clin Oncol 2011; 29: 3659-68.
123. Marx J. Medicine. Fused genes may help explain the origins of prostate cancer. Science 2005; 310: 603.
124. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-8.
125. Lin C, Yang L, Tanasa B, Hutt K, Ju BG, Ohgi K, et al. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 2009; 139: 1069-83.
126. Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet 2010; 42: 668-75.
127. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22.
128. Palmbos PL, Hussain M. Non-castrate metastatic prostate cancer: have the treatment options changed? Semin Oncol 2013; 40: 337-46.
129. Van Poppel H, Klotz L. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists. Int J Urol 2012; 19: 594-601.
130. Crawford ED, Eisenberger MA, Mcleod DG, Spaulding JT, Benson R, Dorr FA, et al. A controlled trial of leuprolide with and without flutamide in prostatic-carcinoma. New Engl J Med 1989; 321: 419-24.
131. Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002; 52: 154-79.
132. Macfarlane RJ, Chi KN. Research in castration-resistant prostate cancer: what does the future hold? Curr Oncol 2010; 17: S80-6.
133. Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009; 6: 76-85.
134. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20.
135. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12.
136. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34-45.
137. Nyquist MD, Dehm SM. Interplay between genomic alterations and androgen receptor signaling during prostate cancer development and progression. Horm Cancer 2013; 4: 61-9.
138. Sharifi N. Mechanisms of androgen receptor activation in castrationresistant prostate cancer. Endocrinology 2013; 154: 4010-7.
139. Green SM, Mostaghel EA, Nelson PS. Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol 2012; 360: 3-13.
140. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997; 57: 314-9.
141. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008; 68: 4447-54.
142. Zhu H, Garcia JA. Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor. Curr Oncol Rep 2013; 15: 105-12.
143. Mitsiades N, Sung CC, Schultz N, Danila DC, He B, Eedunuri VK, et al. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res 2012; 72: 6142-52.
144. Buchanan G, Greenberg NM, Scher HI, Harris JM, Marshall VR, Tilley WD. Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 2001; 7: 1273-81.
145. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999; 59: 2511-5.
146. Jenster G. Ligand-independent activation of the androgen receptor in prostate cancer by growth factors and cytokines. J Pathol 2000; 191: 227-8.
147. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994; 54: 5474-8.
148. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 2004; 6: 517-27.
149. Mahajan NP, Liu Y, Majumder S, Warren MR, Parker CE, Mohler JL, et al. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci USA 2007; 104: 8438-43.
150. Liu Y, Karaca M, Zhang Z, Gioeli D, Earp HS, Whang YE. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases. Oncogene 2010; 29: 3208-16.
151. Kraus S, Gioeli D, Vomastek T, Gordon V, Weber MJ. Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor. Cancer Res 2006; 66: 11047-54.
152. Yang L, Lin C, Jin C, Yang JC, Tanasa B, Li W, et al. lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature 2013; 500: 598-602.
153. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009; 69: 2305-13.
154. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M. B-cellderived lymphotoxin promotes castration-resistant prostate cancer. Nature 2010; 464: 302-5.
155. Setlur SR, Rubin MA. Current thoughts on the role of the androgen receptor and prostate cancer progression. Adv Anat Pathol 2005; 12: 265-70.
156. Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 2013; 155: 1309-22.
157. Mitsiades N. A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer. Cancer Res 2013; 73: 4599-605.
158. Steinkamp MP, O'Mahony OA, Brogley M, Rehman H, Lapensee EW, Dhanasekaran S, et al. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res 2009; 69: 4434-42.
159. Bishr M, Saad F. Overview of the latest treatments for castrationresistant prostate cancer. Nat Rev Urol 2013; 10: 522-8.
160. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-97.
161. Antonarakis ES, Eisenberger MA. Expanding treatment options for metastatic prostate cancer. N Engl J Med 2011; 364: 2055-8.
162. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-90.
163. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138-48.
164. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
165. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990; 173: 534-40.
166. Risstalpers C, Verleunmooijman MCT, Trapman J, Brinkmann AO. Threonine on amino-acid position-868 in the human androgen receptor is essential for androgen-binding specificity and functionalactivity. Biochem Biophys Res Commun 1993; 196: 173-80.
167. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 2000; 6: 703.
168. Matias PM, Carrondo MA, Coelho R, Thomaz M, Zhao XY, Wegg A, et al. Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgenindependent prostate cancer. J Med Chem 2002; 45: 1439-46.
169. Culig Z, Hobisch A, Cronauer MV, Cato ACB, Hittmair A, Radmayr C, et al. Mutant androgen receptor detected in an advancedstage prostatic-carcinoma Is activated by adrenal androgens and progesterone. Mol Endocrinol 1993; 7: 1541-50.
170. Culig Z, Klocker H, Bartsch G, Hobisch A. Androgen receptors in prostate cancer. Endocr Relat Cancer 2002; 9: 155-70.
171. Xu J, Wu RC, O'Malley BW. Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer 2009; 9: 615-30.
172. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003; 63: 149-53.
173. Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci USA 2005; 102: 6201-6.
174. Golshayan AR, Antonarakis ES. Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer. Core Evid 2013; 8: 27-35.
175. Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov 2013; 3: 1020-9.
176. Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, et al. Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife 2013; 2: e00499.
177. Quayle SN, Mawji NR, Wang J, Sadar MD. Androgen receptor decoy molecules block the growth of prostate cancer. Proc Natl Acad Sci USA 2007; 104: 1331-6.
178. Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung JK, et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 2010; 17: 535-46.
179. Myung JK, Banuelos CA, Fernandez JG, Mawji NR, Wang J, Tien AH, et al. An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest 2013; 123: 2948-60.
180. Meimetis LG, Williams DE, Mawji NR, Banuelos CA, Lal AA, Park JJ, et al. Niphatenones, glycerol ethers from the sponge niphates digitalis block androgen receptor transcriptional activity in prostate cancer cells: structure elucidation, synthesis, and biological activity. J Med Chem 2012; 55: 503-14.
181. Nickols NG, Dervan PB. Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide. Proc Natl Acad Sci USA 2007; 104: 10418-23.
182. Chenoweth DM, Harki DA, Phillips JW, Dose C, Dervan PB. Cyclic pyrrole-imidazole polyamides targeted to the androgen response element. J Am Chem Soc 2009; 131: 7182-8.
183. Cherian MT, Wilson EM, Shapiro DJ. A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes. J Biol Chem 2012; 287: 23368-80.
184. Geistlinger TR, McReynolds AC, Guy RK. Ligand-selective inhibition of the interaction of steroid receptor coactivators and estrogen receptor isoforms. Chem Biol 2004; 11: 273-81.
185. Chang CY, Abdo J, Hartney T, McDonnell DP. Development of peptide antagonists for the androgen receptor using combinatorial peptide phage display. Mol Endocrinol 2005; 19: 2478-90.
186. Needham M, Raines S, McPheat J, Stacey C, Ellston J, Hoare S, et al. Differential interaction of steroid hormone receptors with LXXLL motifs in SRC-1a depends on residues f?lanking the motif. J Steroid Biochem Mol Biol 2000; 72: 35-46.
187. Ko L, Cardona GR, Iwasaki T, Bramlett KS, Burris TP, Chin WW. Ser-884 adjacent to the LXXLL motif of coactivator TRBP defines selectivity for ERs and TRs. Mol Endocrinol 2002; 16: 128-40.
188. Heery DM, Hoare S, Hussain S, Parker MG, Sheppard H. Core LXXLL motif sequences in CREB-binding protein, SRC1, and RIP140 define affinity and selectivity for steroid and retinoid receptors. J Biol Chem 2001; 276: 6695-702.
189. Ren Y, Behre E, Ren Z, Zhang J, Wang Q, Fondell JD. Specific structural motifs determine TRAP220 interactions with nuclear hormone receptors. Mol Cell Biol 2000; 20: 5433-46.
190. Axerio-cilies P, Lack NA, Nayana MRS, Chan KH, Yeung A, Leblanc E, et al. Inhibitors of androgen receptor activation function-2 (AF2) site identified through virtual screening. J Med Chem 2011; 54: 6197-205.
191. Lack NA, Axerio-Cilies P, Tavassoli P, Han FQ, Chan KH, Feau C, et al. Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening. J Med Chem 2011; 54: 8563-73.
192. Bisson WH, Cheltsov AV, Bruey-Sedano N, Lin B, Chen J, Goldberger N, et al. Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proc Natl Acad Sci USA 2007; 104: 11927-32.
193. Berruti A, Generali D, Tampellini M. Enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 2448.
194. Foster WR, Car BD, Shi H, Levesque PC, Obermeier MT, Gan J, et al. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate 2011; 71: 480-8.
195. Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 2012; 72: 1494-503.
196. Rathkopf DE, Morris MJ, Fox JJ, Danila DC, Slovin SF, Hager JH, et al. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol 2013; 31: 3525-30.
197. Villoutreix BO, Eudes R, Miteva MA. Structure-based virtual ligand screening: recent success stories. Comb Chem High Throughput Screen 2009; 12: 1000-16.
198. Song CH, Yang SH, Park E, Cho SH, Gong EY, Khadka DB, et al. Structure-based virtual screening and identification of a novel androgen receptor antagonist. J Biol Chem 2012; 287: 30769-80.
199. Shen HC, Shanmugasundaram K, Simon NI, Cai C, Wang H, Chen S, et al. In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancer. Mol Endocrinol 2012; 26: 1836-46.
200. Liu B, Geng G, Lin R, Ren C, Wu JH. Learning from estrogen receptor antagonism: structure-based identification of novel antiandrogens effective against multiple clinically relevant androgen receptor mutants. Chem Biol Drug Des 2012; 79: 300-12.
201. Yang SH, Song CH, Van HT, Park E, Khadka DB, Gong EY, et al. SAR based design of nicotinamides as a novel class of androgen receptor antagonists for prostate cancer. J Med Chem 2013; 56: 3414-8.
202. Voet A, Helsen C, Zhang KY, Claessens F. The discovery of novel human androgen receptor antagonist chemotypes using a combined pharmacophore screening procedure. ChemMedChem 2013; 8: 644-51.
203. McGinley PL, Koh JT. Circumventing anti-androgen resistance by molecular design. J Am Chem Soc 2007; 129: 3822-3.
204. Zhou J, Liu B, Geng G, Wu JH. Study of the impact of the T877A mutation on ligand-induced helix-12 positioning of the androgen receptor resulted in design and synthesis of novel antiandrogens. Proteins 2010; 78: 623-37.
205. Helsen C, Dubois V, Verfaillie A, Young J, Trekels M, Vancraenenbroeck R, et al. Evidence for DNA-binding domain-ligand-binding domain communications in the androgen receptor. Mol Cell Biol 2012; 32: 3033-43.
206. Boutet S, Lomb L, Williams GJ, Barends TRM, Aquila A, Doak RB, et al. High-resolution protein structure determination by serial femtosecond crystallography. Science 2012; 337: 362-64.